---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021886"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:47:39.589674+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M

## Summary
- Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.
- Immune Medicine revenue $27.9M (+18% YoY); MRD revenue $20.0M (+26% YoY).
- Net loss improved to $45.3M from $56.0M; adjusted EBITDA loss $25.9M vs $41.1M.
- FY2022 revenue guidance narrowed to $185-190M from $185-195M; opex now expected below $400M.
- Signed $250M non-dilutive royalty financing with OrbiMed; Epic partnership for clonoSEQ EMR integration.

## SEC filing metadata
- accession: 0000950170-22-021886
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/0000950170-22-021886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/adpt-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021886
- JSON: https://secwatch.observer/filing/0000950170-22-021886.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021886.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp updated its the quarter ended September 30, 2022 guidance (reaffirmed).
  - Period: the quarter ended September 30, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On November 3, 2022, Adaptive Biotechnologies Corporation (the “ Company ”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017022021886/0000950170-22-021886-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.